본문으로 건너뛰기
← 뒤로

Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.

Cancer investigation 2024 Vol.42(3) p. 212-225

Huo M, Zhang J, Hou M, Li J, Bai N, Xu R, Guo J

📝 환자 설명용 한 줄

This study aimed to develop prognostic prediction models for patients diagnosed with synchronous thyroid and breast cancer (TBC).

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 0.74-0.84

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Huo M, Zhang J, et al. (2024). Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.. Cancer investigation, 42(3), 212-225. https://doi.org/10.1080/07357907.2024.2329963
MLA Huo M, et al.. "Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.." Cancer investigation, vol. 42, no. 3, 2024, pp. 212-225.
PMID 38527848

Abstract

This study aimed to develop prognostic prediction models for patients diagnosed with synchronous thyroid and breast cancer (TBC). Utilizing the SEER database, key predictive factors were identified, including T stage of thyroid cancer, T stage of breast cancer, M stage of breast cancer, patient age, thyroid cancer surgery type, and isotope therapy. A nomogram predicting 5-year and 10-year survival rates was constructed and validated, exhibiting strong performance (C-statistic: 0.79 in the development cohort (95% CI: 0.74-0.84), and 0.82 in the validation cohort (95% CI: 0.77-0.89)). The area under the Receiver Operator Characteristic (ROC) curve ranged from 0.798 to 0.883 for both cohorts. Calibration and decision curve analyses further affirmed the model's clinical utility. Stratifying patients into high-risk and low-risk groups using the nomogram revealed significant differences in survival rates ( < 0.0001). The successful development and validation of this nomogram for predicting 5-year and 10-year survival rates in patients with synchronous TBC hold promise for similar patient populations, contributing significantly to cancer research.

MeSH Terms

Humans; Nomograms; Female; SEER Program; Breast Neoplasms; Thyroid Neoplasms; Middle Aged; Prognosis; Aged; Neoplasms, Multiple Primary; Adult; Survival Rate; Neoplasm Staging; ROC Curve